The US name for a break in the usage of Johnson & Johnson Covid’s one-time vaccine is one other blow to hopes to vaccinate the entire world as quickly as attainable.
Well being officers beneficial that states cease utilizing the sting whereas investigating six instances of girls who had uncommon blood clotting occasions mixed with low platelets within the days following vaccination.
J&J introduced that it’s going to additionally “proactively delay the launch of our vaccine in Europe,” the place the European Medicines Company is already reviewing US studies.
The six instances within the US – out of 6.8 million doses of the J&J vaccine administered – seem like comparable to those who raised alarms throughout Europe for the Oxford / AstraZeneca vaccine. Some nations have suspended the Oxford / AstraZeneca vaccine whereas others have imposed age limits. In France it’s not given to anybody below the age of 55, whereas in Germany it’s supplied to these over 60. The UK permits these below 30 to decide on another.
Between them, AstraZeneca and J&J vaccines had been the very best probability for a lot of growing nations. The Oxford / AstraZeneca vaccine is made for no revenue and is straightforward to move and retailer at room temperature. We had been conscious of this – the college and the corporate have dedicated to make it simply accessible. The J&J vaccine is the opposite nice hope as it’s given as one dose reasonably than two. This lowers prices and makes mass vaccination simpler for nations with shaky well being methods.
After extensively analyzing what was occurring with the Oxford / AstraZeneca vaccine, not one of the scientists are very stunned that comparable instances of blood clotting with the J & J model ought to come to mild.